Vir Bio (VIR) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

VIR Stock Forecast

Vir Bio stock forecast is as follows: an average price target of $28.00 (represents a 280.95% upside from VIR’s last price of $7.35) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.

VIR Price Target

The average price target for Vir Bio (VIR) is $28.00 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $28.00. This represents a potential 280.95% upside from VIR's last price of $7.35.

VIR Analyst Ratings

Buy

According to 10 Wall Street analysts, Vir Bio's rating consensus is 'Buy'. The analyst rating breakdown for VIR stock is 0 'Strong Buy' (0.00%), 7 'Buy' (70.00%), 3 'Hold' (30.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Vir Bio Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 02, 2024	Gena Wang	Barclays	$28.00	$9.73	187.77%	280.95%
Jun 05, 2024	Michael Ulz	Morgan Stanley	$15.00	$12.66	18.48%	104.08%
May 21, 2024	Gena Wang	Barclays	$27.00	$9.69	178.64%	267.35%
Feb 21, 2023	Paul Choi	Goldman Sachs	$28.38	$25.74	10.26%	286.12%
May 06, 2022	Joseph Stringer	Needham	$35.00	$21.87	60.04%	376.19%

The latest Vir Bio stock forecast, released on Aug 02, 2024 by Gena Wang from Barclays, set a price target of $28.00, which represents a 187.77% increase from the stock price at the time of the forecast ($9.73), and a 280.95% increase from VIR last price ($7.35).

Vir Bio Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	3
Avg Price Target	-	-	$23.33
Last Closing Price	$7.35	$7.35	$7.35
Upside/Downside	-100.00%	-100.00%	217.41%

In the current month, the average price target of Vir Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vir Bio's last price of $7.35. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 02, 2024	Needham	Buy	Buy	Hold
Aug 02, 2024	Barclays	Overweight	Overweight	Hold
Jun 05, 2024	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Jun 05, 2024	H.C. Wainwright	Buy	Buy	Hold
May 21, 2024	Barclays	Overweight	Overweight	Hold
May 07, 2024	Needham	Buy	Buy	Hold
Mar 15, 2024	H.C. Wainwright	Underperform	Underperform	Hold
Mar 15, 2024	J.P. Morgan	Buy	Buy	Hold
Sep 08, 2023	Bank of America Securities		Neutral	Downgrade
Feb 23, 2023	Goldman Sachs	Buy	Buy	Hold
Feb 21, 2023	Guggenheim		Neutral	Upgrade
Feb 21, 2023	Noble Capital Markets		Outperform	Initialise
Feb 21, 2023	Goldman Sachs		Buy	Upgrade
Sep 14, 2022	SVB Leerink		Outperform	Initialise
May 15, 2022	H.C. Wainwright	Buy	Buy	Hold

Vir Bio's last stock rating was published by Needham on Aug 02, 2024. The company gave VIR a "Buy" rating, the same as its previous rate.

Vir Bio Financial Forecast

Vir Bio Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	$56.29M	$2.64M	$3.80M	$46.71M	$21.79M	$371.43M	$-42.69M	$1.23B	$812.75M	$103.62M	$177.07M	$1.98M	$76.37K	$1.93M	$66.99M	$5.72M	$980.00K	$1.40M
Avg Forecast	$13.57M	$10.96M	$14.60M	$18.20M	$8.17M	$5.54M	$7.53M	$11.71M	$11.18M	$8.71M	$22.39M	$50.15M	$149.61M	$114.22M	$200.72M	$811.05M	$622.96M	$138.25M	$84.56M	$98.64M	$4.81M	$11.01M	$3.90M	$2.90M	$2.57M	$3.75M
High Forecast	$27.37M	$22.11M	$29.43M	$33.85M	$22.26M	$5.78M	$7.53M	$11.71M	$34.10M	$17.70M	$45.14M	$101.12M	$301.68M	$114.22M	$200.72M	$811.05M	$622.96M	$138.25M	$84.56M	$98.64M	$4.81M	$11.01M	$3.90M	$2.90M	$2.57M	$3.75M
Low Forecast	$2.99M	$2.42M	$3.22M	$2.55M	$643.19K	$5.31M	$7.53M	$11.71M	$692.44K	$4.25M	$4.93M	$11.05M	$32.96M	$114.22M	$200.72M	$811.05M	$622.96M	$138.25M	$84.56M	$98.64M	$4.81M	$11.01M	$3.90M	$2.90M	$2.57M	$3.75M
# Analysts	1	1	1	2	4	2	2	2	4	6	3	3	4	4	4	4	3	3	3	3	3	3	3	3	4	4
Surprise %	-	-	-	-	-	-	-	-	5.04%	0.30%	0.17%	0.93%	0.15%	3.25%	-0.21%	1.52%	1.30%	0.75%	2.09%	0.02%	0.02%	0.18%	17.20%	1.97%	0.38%	0.37%

Vir Bio's average Quarter revenue forecast for Mar 24 based on 2 analysts is $11.71M, with a low forecast of $11.71M, and a high forecast of $11.71M. VIR's average Quarter revenue forecast represents a -79.19% decrease compared to the company's last Quarter revenue of $56.29M (Dec 23).

Vir Bio EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	2	4	2	2	2	4	6	3	3	4	4	4	4	3	3	3	3	3	3	3	3	4	4
EBITDA	-	-	-	-	-	-	-	-	$-114.87M	$-186.73M	$-215.19M	$-130.27M	$-159.38M	$208.55M	$-212.24M	$1.11B	$547.41M	$112.25M	$63.27M	$-167.31M	$1.34M	$-83.16M	$-29.75M	$-75.92M	$-62.46M	$-47.12M
Avg Forecast	$-5.66M	$-4.57M	$-6.09M	$-7.59M	$-3.41M	$-2.31M	$-3.14M	$-527.51M	$-4.66M	$-3.63M	$-9.34M	$-564.18M	$-62.41M	$-48.94M	$-86.01M	$-603.40M	$-266.94M	$-59.24M	$-36.24M	$-645.35M	$-2.06M	$-4.72M	$-1.67M	$-50.13M	$-1.10M	$-35.82M
High Forecast	$-1.25M	$-1.01M	$-1.34M	$-1.06M	$-268.32K	$-2.21M	$-3.14M	$-422.01M	$-288.86K	$-1.77M	$-2.06M	$-451.34M	$-13.75M	$-48.94M	$-86.01M	$-482.72M	$-266.94M	$-59.24M	$-36.24M	$-516.28M	$-2.06M	$-4.72M	$-1.67M	$-40.11M	$-1.10M	$-28.65M
Low Forecast	$-11.42M	$-9.22M	$-12.28M	$-14.12M	$-9.29M	$-2.41M	$-3.14M	$-633.01M	$-14.22M	$-7.38M	$-18.83M	$-677.02M	$-125.85M	$-48.94M	$-86.01M	$-724.08M	$-266.94M	$-59.24M	$-36.24M	$-774.42M	$-2.06M	$-4.72M	$-1.67M	$-60.16M	$-1.10M	$-42.98M
Surprise %	-	-	-	-	-	-	-	-	24.64%	51.38%	23.04%	0.23%	2.55%	-4.26%	2.47%	-1.84%	-2.05%	-1.89%	-1.75%	0.26%	-0.65%	17.63%	17.82%	1.51%	56.75%	1.32%

4 analysts predict VIR's average Quarter EBITDA for Dec 22 to be $-62.41M, with a high of $-13.75M and a low of $-125.85M. This is -129.93% lower than Vir Bio's previous annual EBITDA (Sep 22) of $208.55M.

Vir Bio Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	2	4	2	2	2	4	6	3	3	4	4	4	4	3	3	3	3	3	3	3	3	4	4
Net Income	-	-	-	-	-	-	-	-	$-115.92M	$-163.41M	$-194.78M	$-140.96M	$-101.60M	$175.31M	$-76.49M	$518.62M	$525.25M	$110.43M	$61.81M	$-168.91M	$-298.67	$-84.61M	$-31.17M	$-77.24M	$-63.77M	$-48.31M
Avg Forecast	$-127.68M	$-115.69M	$-111.54M	$-107.99M	$-119.19M	$-143.83M	$-122.30M	$-532.55M	$-137.72M	$-164.92M	$-164.44M	$-569.57M	$348.95M	$-69.20M	$44.79M	$-609.17M	$357.78M	$-6.47M	$-65.00M	$-651.51M	$-95.81M	$-81.40M	$-83.92M	$-51.01M	$-90.94M	$-36.72M
High Forecast	$1.74M	$1.58M	$1.52M	$-91.79M	$-92.54M	$1.96M	$1.67M	$-426.04M	$-118.39M	$-119.94M	$2.24M	$-455.66M	$418.74M	$-69.20M	$44.79M	$-487.33M	$357.78M	$-6.47M	$-65.00M	$-521.21M	$-95.81M	$-81.40M	$-83.92M	$-40.81M	$-90.94M	$-29.38M
Low Forecast	$-296.38M	$-268.56M	$-258.92M	$-124.18M	$-134.61M	$-333.87M	$-283.90M	$-639.06M	$-154.63M	$-203.09M	$-381.71M	$-683.48M	$279.16M	$-69.20M	$44.79M	$-731.00M	$357.78M	$-6.47M	$-65.00M	$-781.82M	$-95.81M	$-81.40M	$-83.92M	$-61.21M	$-90.94M	$-44.07M
Surprise %	-	-	-	-	-	-	-	-	0.84%	0.99%	1.18%	0.25%	-0.29%	-2.53%	-1.71%	-0.85%	1.47%	-17.06%	-0.95%	0.26%	0.00%	1.04%	0.37%	1.51%	0.70%	1.32%

Vir Bio's average Quarter net income forecast for Dec 22 is $348.95M, with a range of $279.16M to $418.74M. VIR's average Quarter net income forecast represents a 99.04% increase compared to the company's last Quarter net income of $175.31M (Sep 22).

Vir Bio SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	2	4	2	2	2	4	6	3	3	4	4	4	4	3	3	3	3	3	3	3	3	4	4
SG&A	-	-	-	-	-	-	-	-	$43.09M	$41.08M	$47.10M	$46.78M	$38.74M	$43.17M	$41.59M	$38.26M	$55.78M	$50.50M	$28.78M	$25.74M	$70.94K	$18.86M	$16.39M	$12.65M	$11.81M	$9.22M
Avg Forecast	$152.60M	$123.25M	$164.09M	$204.56M	$91.79M	$62.28M	$84.59M	$131.66M	$125.62M	$97.93M	$251.66M	$563.73M	$37.06M	$1.28B	$2.26B	$92.83M	$7.00B	$1.55B	$950.58M	$1.11B	$54.11M	$123.72M	$43.79M	$32.60M	$28.87M	$42.20M
High Forecast	$307.70M	$248.51M	$330.87M	$380.46M	$250.23M	$64.92M	$84.59M	$131.66M	$383.27M	$198.92M	$507.45M	$1.14B	$44.47M	$1.28B	$2.26B	$111.39M	$7.00B	$1.55B	$950.58M	$1.11B	$54.11M	$123.72M	$43.79M	$32.60M	$28.87M	$42.20M
Low Forecast	$33.62M	$27.15M	$36.15M	$28.65M	$7.23M	$59.64M	$84.59M	$131.66M	$7.78M	$47.82M	$55.44M	$124.19M	$29.64M	$1.28B	$2.26B	$74.26M	$7.00B	$1.55B	$950.58M	$1.11B	$54.11M	$123.72M	$43.79M	$32.60M	$28.87M	$42.20M
Surprise %	-	-	-	-	-	-	-	-	0.34%	0.42%	0.19%	0.08%	1.05%	0.03%	0.02%	0.41%	0.01%	0.03%	0.03%	0.02%	0.00%	0.15%	0.37%	0.39%	0.41%	0.22%

Vir Bio's average Quarter SG&A projection for Mar 24 is $131.66M, based on 2 Wall Street analysts, with a range of $131.66M to $131.66M. The forecast indicates a 205.54% rise compared to VIR last annual SG&A of $43.09M (Dec 23).

Vir Bio EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	2	4	2	2	2	4	6	3	3	4	4	4	4	3	3	3	3	3	3	3	3	4	4
EPS	-	-	-	-	-	-	-	-	$-0.00	$-1.22	$-1.45	$-1.06	$-0.76	$1.32	$-0.58	$3.93	$4.01	$0.85	$0.48	$-1.32	$-0.00	$-0.67	$-0.27	$-0.71	$-0.69	$-0.44
Avg Forecast	$-0.93	$-0.85	$-0.82	$-0.79	$-0.87	$-1.05	$-0.89	$-1.05	$-1.01	$-1.21	$-1.20	$-0.87	$-0.35	$-0.51	$0.33	$3.78	$2.63	$-0.05	$-0.48	$-0.21	$-0.70	$-0.60	$-0.62	$-0.53	$-0.67	$-0.69
High Forecast	$0.01	$0.01	$0.01	$-0.67	$-0.68	$0.01	$0.01	$0.01	$-0.87	$-0.88	$0.02	$0.01	-	$-0.51	$0.33	$3.78	$2.63	$-0.05	$-0.48	$-0.21	$-0.70	$-0.60	$-0.62	$-0.53	$-0.67	$-0.69
Low Forecast	$-2.17	$-1.97	$-1.89	$-0.91	$-0.99	$-2.44	$-2.08	$-2.44	$-1.13	$-1.49	$-2.79	$-2.03	$-0.81	$-0.51	$0.33	$3.78	$2.63	$-0.05	$-0.48	$-0.21	$-0.70	$-0.60	$-0.62	$-0.53	$-0.67	$-0.69
Surprise %	-	-	-	-	-	-	-	-	0.00%	1.01%	1.20%	1.21%	2.19%	-2.60%	-1.76%	1.04%	1.53%	-17.89%	-1.01%	6.20%	0.00%	1.12%	0.44%	1.35%	1.03%	0.64%

According to 4 Wall Street analysts, Vir Bio's projected average Quarter EPS for Dec 22 is $-0.35, with a low estimate of $-0.81 and a high estimate of -. This represents a -126.33% decrease compared to VIR previous annual EPS of $1.32 (Sep 22).

Vir Bio Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
CVAC	CureVac	$2.95	$29.00	883.05%	Buy
VIR	Vir Bio	$7.35	$28.00	280.95%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
VKTX	Viking Therapeutics	$46.70	$97.80	109.42%	Buy
AMLX	Amylyx Pharmaceuticals	$4.28	$8.25	92.76%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
AKRO	Akero Therapeutics	$30.61	$50.00	63.35%	Buy
BPMC	Blueprint Medicines	$96.48	$122.60	27.07%	Buy
KRYS	Krystal Biotech	$169.04	$210.33	24.43%	Buy
MDGL	Madrigal Pharmaceuticals	$306.08	$315.75	3.16%	Buy
PTCT	PTC Therapeutics	$47.02	$48.00	2.08%	Hold

VIR Forecast FAQ

Is Vir Bio a good buy?

Yes, according to 10 Wall Street analysts, Vir Bio (VIR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 70.00% of VIR's total ratings.

What is VIR's price target?

Vir Bio (VIR) average price target is $28 with a range of $28 to $28, implying a 280.95% from its last price of $7.35. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Vir Bio stock go up soon?

According to Wall Street analysts' prediction for VIR stock, the company can go up by 280.95% (from the last price of $7.35 to the average price target of $28), up by 280.95% based on the highest stock price target, and up by 280.95% based on the lowest stock price target.

Can Vir Bio stock reach $11?

VIR's average twelve months analyst stock price target of $28 supports the claim that Vir Bio can reach $11 in the near future.

What are Vir Bio's analysts' financial forecasts?

Vir Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $32.94M (high $47.27M, low $25.19M), average EBITDA is $-536M (high $-428M, low $-648M), average net income is $-918M (high $-515M, low $-1.391B), average SG&A $370.32M (high $531.4M, low $283.12M), and average EPS is $-3.871 (high $-0.636, low $-7.946). VIR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $57.33M (high $112.76M, low $11.17M), average EBITDA is $-23.918M (high $-4.66M, low $-47.04M), average net income is $-463M (high $-86.956M, low $-948M), average SG&A $644.49M (high $1.27B, low $125.57M), and average EPS is $-3.387 (high $-0.636, low $-6.938).

Did the VIR's actual financial results beat the analysts' financial forecasts?

Based on Vir Bio's last annual report (Dec 2023), the company's revenue was $86.18M, which missed the average analysts forecast of $92.42M by -6.76%. Apple's EBITDA was $-684M, beating the average prediction of $-582M by 17.62%. The company's net income was $-615M, missing the average estimation of $-1.037B by -40.67%. Apple's SG&A was $178.05M, missing the average forecast of $1.04B by -82.86%. Lastly, the company's EPS was $-0.0046, missing the average prediction of $-4.293 by -99.89%. In terms of the last quarterly report (Dec 2023), Vir Bio's revenue was $56.29M, beating the average analysts' forecast of $11.18M by 403.68%. The company's EBITDA was $-115M, beating the average prediction of $-4.662M by 2363.85%. Vir Bio's net income was $-116M, missing the average estimation of $-138M by -15.83%. The company's SG&A was $43.09M, missing the average forecast of $125.62M by -65.70%. Lastly, the company's EPS was $-0.0009, missing the average prediction of $-1.008 by -99.91%